Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 7.

Journal Article

Christgen, Matthias, Gluz, Oleg, Harbeck, Nadia, Kates, Ronald E., Raap, Mieke, Christgen, Henriette, Clemens, Michael, Malter, Wolfram, Nuding, Benno, Aktas, Bahriye, Kuemmel, Sherko, Reimer, Toralf, Stefek, Andrea, Krabisch, Petra, Just, Marianne, Augustin, Doris, Graeser, Monika, Baehner, Frederick, Wuerstlein, Rachel, Nitz, Ulrike and Kreipe, Hans (2020). Differential impact of prognostic parameters in hormone receptor-positive lobular breast cancer. Cancer, 126 (22). S. 4847 - 4859. HOBOKEN: WILEY. ISSN 1097-0142

Degenhardt, Tom, Kreipe, Hans Heinrich, Gluz, Oleg, Kates, Ronald E., Liedtke, Cornelia, Kraemer, Stefan, Clemens, Michael R., Nuding, Benno, Reimer, Toralf, Aktas, Bahriye, Kummel, Sherko, Just, Marianne, Lorenz-Salehi, Fatemeh, Uleer, Christoph, Stefek, Andrea, Heyl, Volker, Wuerstlein, Rachel, Nitz, Ulrike, Harbeck, Nadia and Christgen, Matthias (2016). Prognostic impact of androgen receptor (AR) and forkhead box A1 (FOXA1) in early HER2-negative primary breast cancer: A translational substudy of the prospective phase III WSG-PlanB-trial. J. Clin. Oncol., 34 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Gluz, Oleg, Nitz, Ulrike, Christgen, Matthias, Kates, Ronald E., Clemens, Michael, Kraemer, Stefan, Nuding, Benno, Reimer, Toralf, Aktas, Bahriye, Kummel, Sherko, Just, Marianne, Stefek, Andrea, Lorenz-Salehi, Fatemeh, Krabisch, Petra, Liedtke, Cornelia, Svedman, Christer, Shak, Steven, Wuerstlein, Rachel, Kreipe, Hans Heinrich and Harbeck, Nadia (2016). Prognostic impact of 21 Gene Recurrence Score, IHC4, and central grade in high-risk HR+/HER2-early breast cancer (EBC): 5-year results of the prospective Phase III WSG PlanB trial. J. Clin. Oncol., 34 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Harbeck, Nadia, Gluz, Oleg, Clemens, Michael R., Malter, Wolfram, Reimer, Toralf, Nuding, Benno, Aktas, Bahriye, Stefek, Andrea, Pollmanns, Anke, Lorenz-Salehi, Fatemeh, Uleer, Christoph, Krabisch, Petra, Kummel, Sherko, Liedtke, Cornelia, Shak, Steven, Wuerstlein, Rachel, Christgen, Matthias, Kates, Ronald, Kreipe, Hans Heinrich and Nitz, Ulrike (2017). Prospective WSG phase III PlanB trial: Final analysis of adjuvant 4xEC -> 4x doc vs. 6x docetaxel/cyclophospham ide in patients with high clinical risk and intermediate-to-high genomic risk HER2-negative, early breast cancer. J. Clin. Oncol., 35. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Nitz, Ulrike, Gluz, Oleg, Christgen, Matthias, Kates, Ronald E., Clemens, Michael, Malter, Wolfram, Nuding, Benno, Aktas, Bahriye, Kuemmel, Sherko, Reimer, Toralf, Stefek, Andrea, Lorenz-Salehi, Fatemeh, Krabisch, Petra, Just, Marianne, Augustin, Doris, Liedtke, Cornelia, Chao, Calvin, Shak, Steven, Wuerstlein, Rachel, Kreipe, Hans H. and Harbeck, Nadia (2017). Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial. Breast Cancer Res. Treat., 165 (3). S. 573 - 584. NEW YORK: SPRINGER. ISSN 1573-7217

Nitz, Ulrike, Gluz, Oleg, Clemens, Michael, Malter, Wolfram, Reimer, Toralf, Nuding, Benno, Aktas, Bahriye, Stefek, Andrea, Pollmanns, Anke, Lorenz-Salehi, Fatemeh, Uleer, Christoph, Krabisch, Petra, Kuemmel, Sherko, Liedtke, Cornelia, Shak, Steven, Wuerstlein, Rachel, Christgen, Matthias, Kates, Ronald E., Kreipe, Hans H., Harbeck, Nadia, Ackermann, S., Aktas, B., Augustin, D., Baake, G., Baumann, K., Berger, R., Bettscheider, J., Bischoff, J., Clemens, M., Deryal, M., Dubbers, H., Duchting, D., Dunnebacke, J., Fett, W., Fietz, T., Fischer, H., Forner, M., Forstbauer, H., Freese, K., Geberth, M., Glados, M., Gnauert, K., Goette, O., Gohring, U., Goppinger, A., Grafe, A., Hackenberg, R., Hackmann, J., Hellriegel, M., Heyl, V., Hoestermann, C., Hoffmann, G., Hofmann, M., Hucke, J., Jackisch, C., Jungberg, P., Just, M., Kahl, C., Klare, P., Kogel, M., Kohls, A., Amrawy, B. Konigs-El, Konnecke, P., Krabisch, P., Kraudelt, S., Kremers, S., Kummel, S., Kurbacher, C., Kusche, J., Liedtke, B., Liedtke, C., Link, H., Lorenz, R., Salehi, F. Lorenz, Lubbe, K., Malter, W., Melekian, B., Mobus, V., Montenarh, M., Mueller, V., Mundhenke, C., Niederle, N., Nitz, U., Noesselt, T., Oberhoff, C., Paas, L., Paepke, S., Pollmanns, A., Reichert, D., Reimer, T., Romann, D., Ruhland, T., Runde, V., Salem, M., Schlosser, A., Schneider, A., Schrader, I., Schulz, H., Schumacher, C., Schwickerath, J., Soling, U., Stauder, H., Stefek, A., Steinmetz, T., Stickeler, E., Terhaag, J., Thomssen, C., Tome, O., Uleer, C., Warm, M., Wachsmann, G., Wacker, J., Wiebringhaus, H., Wiest, W., Wolfgarten, M., Nitz, U., Christgen, H., Kreipe, H., Buehne, C., Gluz, O., Hansen, K., Hofmann, D., Kates, R., Mangold, M., Mathissen, M., Raeth, P., Renner, I., Reiser, I., Schumacher, J., Staedele, M. and Walter-Kirst, R. (2019). West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer. J. Clin. Oncol., 37 (10). S. 799 - 811. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Nitz, Ulrike, Gluz, Oleg, Kreipe, Hans H., Christgen, Matthias, Kuemmel, Sherko, Baehner, Frederick L., Shak, Steven, Aktas, Bahriye, Braun, Michael, Ludtke-Heckenkamp, Kerstin, Forstbauer, Helmut, Grischke, Eva-Maria, Nuding, Benno, Darsow, Maren, Schumacher, Claudia, Krauss, Katja, Malter, Wolfram, Thill, Marc, Warm, Mathias, Wuerstlein, Rachel, Kates, Ronald E. and Harbeck, Nadia (2020). The run-in phase of the prospective WSG-ADAPT HR+/HER2-trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer. Ther. Adv. Med. Oncol., 12. LONDON: SAGE PUBLICATIONS LTD. ISSN 1758-8359

This list was generated on Tue Oct 26 02:20:08 2021 CEST.